of haptoglobin, hemopexin, or heme oxygenase-1 (18) . However, it is currently unknown whether circulating cell-free hemoglobin can be detected in humans with sepsis, or whether the presence of cell-free hemoglobin in sepsis is associated with poor clinical outcomes. Additionally, although evidence of oxidant stress and lipid peroxidation as measured by plasma concentrations of F 2 -isoprostanes has been described in patients with sepsis and is associated with renal, hepatic, and coagulation failure, and mortality (19) , the role of cell-free hemoglobin in driving lipid peroxidation in sepsis is unknown.
Acetaminophen, at normal therapeutic concentrations, is a potent inhibitor of hemoprotein-mediated lipid peroxidation owing to its ability to reduce the ferryl-protoporphyrin radical generated with release of hemoproteins into the circulation. Heme-protein induced oxidation of arachidonic acid in lipid membranes, and production of isoprostanes and isofurans is blocked by therapeutic concentrations of acetaminophen (20, 21) . In experimental studies in rats, acetaminophen was highly effective in preventing oxidative damage and renal failure in the setting of myoglobinemia due to rhabdomyolysis (21) ; however, the potential for acetaminophen to inhibit hemoproteinmediated lipid peroxidation has not been studied in humans.
We conducted a retrospective analysis of a prospectively collected cohort to test the hypothesis that high concentrations of cell-free hemoglobin in patients with sepsis are associated with an increased risk of in-hospital mortality. We also hypothesized that exposure to acetaminophen in this patient population would be associated with a protective effect in the setting of cell-free hemoglobin via a reduction of oxidative stress as measured by plasma F 2 -isoprostanes.
MATERIALS AND METHODS

Patients
The study population consisted of 400 consecutive patients who were prospectively enrolled in the Validating Acute Lung Injury Markers for Diagnosis (VALID) study (22) and had the diagnosis of sepsis, as defined by the consensus definition (23), on enrollment. The VALID study includes patients ≥ 18 yr old admitted to the Vanderbilt ICUs for at least 2 days and has been approved by the Vanderbilt Institutional Review Board. Plasma samples were obtained at enrollment on the morning of ICU day 2 and again 48 hrs later. To minimize hemolysis, blood was preferentially drawn through a central venous catheter before using peripheral intravenous access or peripheral blood draw. All blood samples were immediately cooled, centrifuged at 3000 rpm for 10 mins, and plasma was frozen at -80°C.
Inclusion/Exclusion Criteria
All 400 patients with sepsis on enrollment were considered for inclusion in the cell-free hemoglobin analysis if they had plasma available from the enrollment time point unless gross hemolysis was detected in their plasma sample. For the acetaminophen analysis, all 400 patients were considered for inclusion if they had a nonhemolyzed enrollment blood draw and had data from the medication administration record available as to timing and doses of acetaminophen administered during the 96 hrs of the VALID study period. For the F 2 -isoprostane analysis, a subgroup of patients were consecutively included if they had a plasma cell-free hemoglobin concentration of 10-70 mg/dL on enrollment, had received either the highest quartile cumulative dose of acetaminophen or no acetaminophen in the 48 hrs after enrollment, and had a plasma sample available at 48 hrs after enrollment. This cell-free hemoglobin range was chosen as the risk factor (detectable cell-free hemoglobin) would be present and the median and interquartile range (IQR) of the cell-free hemoglobin concentrations would be similar to the primary analysis.
Measurements
Measurements were made in plasma obtained on the morning of ICU day 2 (cell-free hemoglobin) at the time of enrollment into the VALID study and 48 hrs later on ICU day 4 (F 2 -isoprostanes). Cell-free hemoglobin was measured using a HemoCue Plasma Low/Hb system (Angelholm, Sweden) that has a lower limit of detection of 10 mg/dL. Plasma samples with undetectable cell-free hemoglobin were considered to have concentrations of 0 mg/dL in the statistical analyses. F 2 -isoprostane measurements were made using stable isotope dilution negative ion chemical ionization gas chromatography mass spectrometry (24) .
Statistical Analysis
The primary analysis for this cohort study was hospital mortality in relation to cell-free hemoglobin concentration. The secondary analyses were in-hospital mortality in the setting of cell-free hemoglobin and variable acetaminophen exposure during the entire VALID enrollment period, along with plasma F 2 -isoprostane concentrations in the setting of cell-free hemoglobin and variable acetaminophen exposure in the 48 hrs prior to the blood draw used to measure F 2 -isoprostanes.
As the majority of the data are not normally distributed, data are expressed as median values with IQR for continuous variables and frequencies for categorical variables. Univariate analyses were conducted using Wilcoxon's rank-sum test for continuous variables, Fisher's exact test for categorical variables of two groups, Pearson's chi-square test for a trend for categorical variables of greater than two groups, and Spearman's rank correlation coefficient to assess correlation between two continuous variables. Known risk factors for both poor outcomes and elevated cell-free hemoglobin and significant variables from univariable analyses that could influence cell-free hemoglobin levels were included in the multivariable logistic regression models used to analyze risks of in-hospital mortality. IBM SPSS Statistics (version 19.0, Chicago, IL) was used for statistical analysis; a two-sided significance level of 0.05 was used for statistical inference.
RESULTS
Clinical Characteristics
Of the 400 patients with sepsis, nine were excluded from the primary analysis due to overt signs of hemolysis during processing. The remaining 391 patients defined the primary study population. Patients were predominantly in the medical ICU (72.1%), followed by the surgical (21.5%), trauma (3.3%), and cardiovascular ICUs (3.1%). Table 1 compares baseline characteristics between hospital survivors and nonsurvivors. Survivors were younger, had a lower severity of illness by Acute Physiology and Chronic Health Evaluation (APACHE) II score, and were less likely to have chronic liver disease. The median plasma cell-free hemoglobin in all patients measured at enrollment was 20 mg/dL, IQR 10-30. Cell-free hemoglobin was undetectable in 75 (19.2%) of patients. Compared to patients with no detectable cell-free hemoglobin (< 10 mg/ dL), patients with any detectable cell-free hemoglobin were similar in regards to age, gender, APACHE II score, chronic liver disease, and percentage with severe sepsis or septic shock; however, six (8.1%) of patients with undetectable cell-free hemoglobin died compared to 79 (24.9%) of the patients with any amount of detectable cell-free hemoglobin (p ≤ 0.001).
In-Hospital Mortality Related to Cell-Free Hemoglobin Concentrations
Of the 391 patients in the final analysis, 85 (21.7%) died during hospitalization. Nonsurvivors had significantly higher free hemoglobin concentrations (median 20 mg/dL, IQR 10-40) (Fig. 1) compared to survivors (10 mg/dL, IQR 10-30, p = 0.002). In an unadjusted analysis, higher concentrations of free hemoglobin were associated with an increasing risk of in-hospital mortality (p = 0.004) (Fig. 2) .
A multivariable logistic regression model was used to examine the association between plasma free hemoglobin concentration and mortality. After controlling for age, APACHE II score, requirement of hemodialysis, and chronic liver disease, there was a significant increase in risk of in-hospital mortality in patients with higher concentrations of cell-free hemoglobin (odds ratio
[OR] 1.078 per 10 mg/dL increase in plasma cell-free hemoglobin concentration, 95% confidence interval [CI] 1.012-1.149, p = 0.02) ( Table 2) .
Clinical Characteristics of Patients With Acetaminophen Exposure
Of the 391 patients included in the primary analysis, accurate records regarding presence or absence of acetaminophen exposure and dose during the VALID enrollment period were available on 292 patients from the electronic medication administration record. Patients included in the acetaminophen analysis were similar to patients in the primary analysis ( Table 3) . During the 96 hrs of VALID enrollment, 146 (50%) of these 292 patients received any dose of acetaminophen and the median cumulative acetaminophen dose among all patients was 325 mg, IQR 0-1500 (Table 3) .
In-Hospital Mortality and Acetaminophen Exposure
Of the 292 patients in this analysis, 57 (19.6%) died during hospitalization. Survivors were more likely to have received some amount of acetaminophen (p = 0.008) along with being exposed to higher cumulative doses (median 650 mg, IQR 0-1950) compared to nonsurvivors (median 0 mg, IQR 0-650, p = 0.002). After controlling for age, the presence of chronic liver disease, APACHE II score, and cell-free hemoglobin concentration receiving any dose of acetaminophen had a protective association with in-hospital mortality (OR 0.481, 95% CI 0.252-0.916, p = 0.026) ( Table 4 ). In addition, when analyzing only the subset of patients with no detectable plasma cell-free hemoglobin (n = 34), the associated protective effect between acetaminophen and mortality was no longer apparent (OR 1.328, 95% CI 0.103-17.164, p = 0.852).
F 2 -Isoprostane Concentrations in the Setting of Variable Acetaminophen Exposure
We next determined whether administration of acetaminophen was associated with a reduction in lipid peroxidation in the setting of circulating cell-free hemoglobin in a nested case control study. We studied 20 consecutively selected patients from the larger cohort of 391 sepsis patients who had plasma cell-free hemoglobin concentrations of 10-70 mg/dL measured on enrollment. Half of the patients (n = 10) had received no acetaminophen, and half of the patients had received a cumulative acetaminophen dose in the highest quartile prior to a second blood draw 48 hrs after enrollment for measurement of F 2 -isoprostanes. There was no difference in cell-free hemoglobin concentrations between the acetaminophen and no acetaminophen groups (20mg/dL compared to 30mg/dL, respectively, p = 0.409). Patients who had received acetaminophen in the 48 hrs prior to the second blood draw had significantly lower concentrations of F 2 -isoprostanes (18.5 pg/mL, IQR 9-22.2) compared to those who received no acetaminophen (42 pg/mL, IQR 29.7-86, p = 0.009) (Fig. 3) . In addition, the cumulative dose of acetaminophen received was inversely correlated with F 2 -isoprostane concentrations measured 48 hrs after enrollment (r s = -0.669, p = 0.001).
DISCUSSION
In this large study of critically ill patients with sepsis, there was a significant association between plasma cell-free hemoglobin concentrations and in-hospital mortality even when controlling for factors that might predispose to higher circulating cell-free hemoglobin concentrations such as hemodialysis and chronic liver disease. In addition, sepsis patients who received acetaminophen, a potent inhibitor of hemoprotein-mediated lipid peroxidation, early in their hospital course had significantly lower hospital mortality and a decrease in oxidative stress as measured by circulating F 2 -isoprostanes. To our knowledge, this study is the first description of an association of cell-free hemoglobin concentrations with mortality in a large population of patients with sepsis. In addition, a potential protective effect of acetaminophen in sepsis has not previously been reported. The odds ratio for Acute Physiology and Chronic Health Evaluation II score is for every one point above a score of seven. The odds ratio for cell-free hemoglobin concentration is for an increment of every 10 mg/dL > 0 mg/dL. The Hosmer and Lemeshow goodness-of-fit statistic for this model is 0.605.
Figure 2.
In-hospital mortality based on increasing concentrations of plasma cell-free hemoglobin. There was an increasing mortality trend among patients with higher plasma cell-free hemoglobin concentrations (Pearson Χ 2 for a trend, p = 0.004).
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In experimental studies, circulating cell-free hemoglobin has been observed in rodents with sepsis, and higher concentrations were associated with mortality (18) . There are several potential mechanisms by which cell-free hemoglobin could be injurious in the setting of sepsis. Cell-free hemoglobin can scavenge nitric oxide leading to vasoconstriction (1, 2, 6, 8, 9) . In addition, when hemoglobin is released into the extracellular compartment, ferrous heme is oxidized to ferryl heme protoporphyrin radical species, which are potent oxidants that cause lipid peroxidation (21, 25) . Both vasoconstriction and lipid peroxidation have been associated with poor outcomes in other patient populations (1-3,  6, 8, 9, 12, 17) .
By virtue of its reducing properties, acetaminophen can inhibit the production of radicals in the setting of free hemoproteins such as hemoglobin or myoglobin (20, 21, 26, 27) . In animal models, acetaminophen is protective against acute kidney injury caused by rhabdomyolysis (21) . Because cell-free hemoglobin was detectable in the majority of severe sepsis patients and was associated with poor clinical outcomes, we hypothesized that exposure to acetaminophen would be protective by limiting hemoglobin-mediated lipid peroxidation. In fact, not only did we find an independent association between treatment with acetaminophen and reduced mortality in the setting of an oxidant stimulus (cell-free hemoglobin) but also we found that patients who received the highest cumulative amount of acetaminophen had a reduction in lipid peroxidation as measured by F 2 -isoprostanes compared to patients who received no acetaminophen.
Plasma cell-free hemoglobin concentrations measured in our patient population are similar to concentrations reported in other disease states such as sickle cell anemia and those undergoing dialysis or cardiac bypass (1) (2) (3) (4) (5) . However, the current study suggests a different interaction between acetaminophen and sepsis compared to a recent observational study of over 700 critically ill patients that reported an association between acetaminophen administration and increased mortality in the subgroup with sepsis (28). Unlike that study, which only analyzed acetaminophen given for fever and thus may have been subject to confounding by indication, our study analyzed any form of acetaminophen given for any indication, including as a pain reliever in combination with opiates. Furthermore, acetaminophen may only be protective in a subset of sepsis patients who have detectable concentrations of plasma cell-free hemoglobin as there was no associated protective effect in our study when analyzing only patients with undetectable cell-free hemoglobin.
This study has several limitations. First, it is not possible to determine causation from this observational study. Although we adjusted for multiple potential confounders in our multivariable analysis, it is possible that elevated plasma cellfree hemoglobin is a marker of more serious illness rather than a mediator. Second, although the sample size for the primary analysis was large, the sample sizes for secondary analyses were smaller due to data on acetaminophen exposure being available only in a subset of patients as well as there being relatively few patients who met the inclusion criteria for the analysis of F 2 -isoprostanes. Third, although we controlled for severity of illness and conditions that may preclude treatment with acetaminophen, that is, chronic liver disease or a high severity of illness, when analyzing the effect of acetaminophen on mortality, it is possible that the association between acetaminophen dose and improved clinical outcomes is still confounded. Data describing the reasons for acetaminophen administration and route were not available, which further limits our ability to control for potential confounders. In addition, the association between higher F 2 -isoprostane concentrations in patients having received no acetaminophen compared to patients receiving the highest quartile of acetaminophen may be a marker of severity of illness rather than a pharmacologic effect of acetaminophen. The potential for confounding is mitigated to some extent by the strong, inverse correlation between cumulative acetaminophen dose and isoprostane concentrations. The lower limit of detection for our cell-free hemoglobin assay being 10 mg/dL along with the inability to determine which patients in the VALID study had disseminated intravascular coagulation reduces the granularity of the data we have presented. Finally, we cannot account for patients who died during the acetaminophen exposure window, which would decrease their chance to receive acetaminophen, although these patients accounted for < 5% (n = 14) of patients included in the acetaminophen analysis. There is no survivor bias in the F 2 -isoprostane analysis as none of the patients died during the potential acetaminophen exposure window.
CONCLUSIONS
In critically ill patients with sepsis, cell-free hemoglobin can commonly be detected and higher concentrations are associated with a higher risk of death. In addition, acetaminophen exposure during early sepsis and in the setting of increased cell-free hemoglobin is associated with a lower risk death, and evidence of oxidative stress is decreased in patients with detectable cell-free hemoglobin who received acetaminophen. These observations suggest that cell-free hemoglobin could be an important mediator of oxidative injury in clinical sepsis and that acetaminophen might attenuate this injury. Prospective studies are needed to more specifically define the injurious role of cellfree hemoglobin in sepsis and the potential protective effect of acetaminophen in this clinical setting. The odds ratio for cell-free hemoglobin concentration is for an increment of every 10 mg/dL > 0 mg/dL. Acetaminophen refers to a patient receiving any amount of acetaminophen over the 96-hr study period compared to none. The Hosmer and Lemeshow goodness-of-fit statistic for this model is 0.518.
